Global Biomarkers Market, Size, Share, Trends, Forecast (2024 – 2032)

Introduction:

Biomarkers, also known as molecular markers or signature molecules, can be used to check that how body responds to any illness or disease being treated. They are used to examine the functions of the organs and other health conditions, in simple words. They are also used in imaging technology to provide precise imaging of tumours and other problems in oncology. They are also used in early phase clinical trials to assess drug results and effects.

Global Biomarkers Market Size & Growth:

The global biomarkers market was valued at $XX Billion in 2018 and is estimated to reach $XX Billion by 2026, growing at a CAGR of around X.XX% during the forecast period. Growth in the global biomarker industry is driven primarily by factors such as growing biomarker diagnostic applications, rising R&D funding for pharmaceutical and biotech companies, greater prevalence of CROs and low cost clinical trials in developing countries, high cancer prevalence and new research initiatives. On the other hand, the major factors hampering the growth of this market are high capital investment and a low cost-benefit ratio, poorly suited regulatory and reimbursement processes, and technical issues related to sample collection and storage. Moreover, paradigm shift towards personalized medicine for cancer treatments, development of OMICS technology and rising interdisciplinary systems biology approach is expected to drive the market for biomarkers.

Global Biomarkers Market Segmentation:

The global biomarkers market is segregated on the basis of product, type, disease indication, application, and geography. By product, the biomarkers market is segmented into consumables, services, and software. The consumables segment accounted for the largest share of the global biomarkers market, primarily due to the increasing use of reagent kits and assays for biomarker testing and the higher frequency of purchase of consumables.

Based on type segment, the biomarkers market is bifurcated into safety, efficacy, and validation biomarkers. The efficacy biomarkers segment is further segmented into predictive, surrogate, pharmacodynamics, and prognostic biomarkers.

By disease indication, this report is segmented into cancer, cardiovascular disorders, neurological disorders, immunological disorders, and other disease indications. Cancer forms the largest segment primarily due to the rising prevalence of cancer globally and the growing application of biomarkers in cancer diagnostics.

Biomarkers are mainly used in diagnostics, drug discovery & development, personalized medicine, disease risk assessment, and other applications. Moreover, increasing use of biomarkers for the diagnosis of multiple diseases, including cancer, cardiovascular disorders, and neurological disorders is the major factor that drives the growth of diagnostic segment of the biomarker market.

Based on region, has been segmented into North America, South America, Europe, Asia-Pacific, and the Middle East & Africa. North America held the largest market share for biomarkers attributed to increasing developments in diagnostic applications of biomarkers, spurring R&D funding for biomarker research, and high prevalence of cancer. Europe accounts for the second-largest share in the global biomarkers market owing to the presence of favorable government initiatives and laws, large target population base, rising prevalence of lifestyle-associated conditions, and increasing adoption rate of biomarker dependent diagnostic tests.

 Global Biomarkers Market Trends:

• In March 2020, F. Hoffmann-La Roche Ltd declared the approval by the US Food and Drug Administration (FDA) for its CINtec PLUS Cytology as the first biomarker-based triage test for women whose primary cervical cancer screening results are positive for the human papillomavirus (HPV) using the cobas 4800 HPV Test
• In November 2019, Merck and Personalis, a cancer genomics company, come into into a partnership to identify and develop novel clinical biomarkers for cancer therapies. Under the terms of the partnership, Merck strategies to use Personalis’ newest cancer immunogenomics platform ImmunoID NeXT for clinical biomarker identification and development

Global Biomarkers Market Research Report Include:

• An executive summary condensing the whole report such that essential authority can rapidly twist up doubtlessly acquainted with brief overview and conclusion.
• To have complete market analysis through industry value chain analysis, porter’s five, PESTLE, SWOT analysis, and Y-o-Y analysis.
• Regional and global diversity is analyzed with the major countries and the unions. Scrutinizing the revenue generation on Year-On-Year
• Identifying DROC in the current market and their impact in altering the market dynamics.
• Competitive landscape analysis to identify the merger and acquisition which will have a comparative financial analysis with major competitors.
• Expertise investment opportunities by analyst to the individual and organization to have better foothold in the market.
• Identify the latest developments, market shares and strategies that are employed by the major market players, such as
• Qiagen N.V.
• Perkinelmer, Inc.
• Bio-Rad Laboratories, Inc.
• Hoffmann-La Roche Ltd
• MilliporeSigma

Along with these companies, there were many other companies considered/ cited in the report while analyzing the biomarkers market. These companies hold substantial share-owning to the nature of the industry whereas rest of the market shares are marginal chunks to regional and local level manufacturers. other players have considerable presence owing to its robust brand image, geographical reach, and strong customer base.